9.710USD-6.00%Mkt Cap: 91.02M USDP/E: —Last update: 2026-05-26
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral scle…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap91.02M USD
Enterprise Value27.60M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-105.61M USD
Revenue/Share—
Last Price9.710 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.66
EV/Revenue—
P/S—
P/B3.38
EPS (TTM)-24.09
EPS (Forward)—
52W Range
2.64061% of range14.21
52W High14.21 USD
52W Low2.640 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-380.03%
ROA-114.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.73M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-18.56%
Net Debt-66.99M USD
Net Debt/EBITDA1.60
Balance Sheet
Debt/Equity0.03
Current Ratio10.38
Quick Ratio10.15
Book Value/Sh2.977 USD
Cash/Share7.205 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateSep 18, 2025
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)16.00 USD
Target Range16.00 USD – 16.00 USD
# Analysts1
Ownership
Shares Out.9.39M
Float6.41M
Insiders4.46%
Institutions70.34%
Short Interest
Short Ratio1.5d
Short % Float1.05%
Short % Out.0.62%
Shares Short58.00K
Short (prev mo.)100.21K
Technical
SMA 509.559 (+1.6%)
SMA 2005.951 (+63.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)42.40K
Avg Vol (10d)54.05K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—